PR Newswire PharmaOriginal article
RECKITT ANNOUNCES U.S. FDA APPROVAL OF MUCINEX® 12HR COLD & FEVER MULTI-SYMPTOM, THE FIRST OTC INNOVATION IN THE COLD & FLU CATEGORY IN 14 YEARS
RegulatoryapprovedMucinex 12HR Cold & Fever Multi-SymptomPositive
AI Analysis
Summary
Reckitt announced U.S. FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first new OTC innovation in the cold and flu category in 14 years. The drug treats fever, cough, chest congestion, and body pain with 12-hour duration.
Outcome Details
FDA approval of OTC cold and flu medication treating fever, cough, chest congestion, and body pain for 12 hours; first new OTC innovation in the cold and flu category in 14 years
Importance:7/10
Sentiment:
0.80
FDA approvalOTCCold and fluProduct launchInnovation
Read the original article
Published by PR Newswire Pharma on August 5, 2026 1:05 PM